A trial fibrillation (AF) is the most common chronic arrhythmia, occurring in approximately 2.2 million Americans. 1 The incidence of AF approximately doubles with each decade of adult life.
shortening of the atrial refractory period and loss of normal lengthening of atrial refractoriness at slower heart rates. This is termed atrial electrical remodeling and in some cases may be reversed by maintenance of sinus rhythm. 7 Anatomic remodeling of the atria also occurs with prolonged AF. Fibrosis or inflammation of the atrial cells may act as substrate for development of atrial arrhythmias.
There is usually a trigger for development of AF, including change in autonomic tone or change in atrial wall tension. In HF, AF may occur as a result of distension of the atria due to pressure or volume overload of either the right or the left ventricle.
Complications from AF occur because of several mechanisms. First, stasis of blood in the atria may lead to arterial thromobemboli, which in turn may cause stroke or pulmonary embolism. Second, a loss of the atrial contribution to ventricular filling ("atrial kick") results in a decrease of up to 20% of cardiac output. 8 Patients with already-reduced systolic function may be reliant on this extra 20% of blood provided during the atrial kick and may experience hemodynamic compromise related to further reduction of cardiac output. Third, AF may cause a tachycardia-induced cardiomyopathy or worsen a cardiomyopathy caused by another disorder. 3 Last, side effects from antiarrhythmic medications may also contribute to complications. sinus rhythm, prevention of recurrences, and prevention of thromboembolic events. Recent trials have focused on determining the benefits of rate control versus rhythm control and will be addressed later in this article.
Advantages of rate control include reduction of symptoms, no antiarrhythmic drug effects, and no tachycardia-induced cardiomyopathy. Disadvantages of rate control include loss of atrial kick/cardiac output and subsequent adverse hemodynamics, need for long-term anticoagulation, and potential for atrial remodeling, which may result in permanent AF.
Advantages of rhythm control include avoidance of atrial remodeling, improved hemodynamics, relief from symptoms, possible enhancement of exercise capacity, and the possible reduction of thromboembolic events. 9 Disadvantages of rhythm control include adverse effects of antiarrhythmic drugs and the likelihood of recurrence of AF.
Recent clinical trials have addressed the issue of rate control versus rhythm control as the primary management approach to AF in the general cardiology population. The Atrial Fibrillation Follow-up Investigation in Rhythm Management (AFFIRM) trial demonstrated no significant difference in overall mortality between rate control versus rhythm control groups, with both groups receiving anticoagulation with warfarin. Both groups had similar outcomes in composite end points of death, major bleeding, disabling stroke, or anoxic encephalopathy. 10 The Pharmacological Intervention in Atrial Fibrillation (PIAF) trial demonstrated that rhythm control was not better than rate control with respect to symptoms, quality of life, or number of hospitalizations of patients with persistent AF. 11 The Rate Control Versus Electrical Cardioversion (RACE) trial showed no significant difference in primary end points between the rate control arm and the electrocardioversion rhythm control arm. 12 Finally, the Strategies of Treatment of Atrial Fibrillation (STAF) trial demonstrated that rate control was not inferior to rhythm control in terms of morbidity, mortality, and quality of life. 13 Overall these studies show that symptoms may be relieved by either management strategy, and exercise tolerance may be slightly improved in patients maintaining sinus rhythm.
The optimal treatment strategy in the HF population has not been defined. The Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial is currently under way. This is a prospective, multicenter trial that will randomize 1450 CHF patients with left-ventricular (LV) systolic dysfunction to either rhythm or rate control group. The primary objective is to compare these 2 treatment strategies with respect to cardiovascular mortality. 14 
Treatment Approach for Onset of AF
The immediate management approach of AF is to determine hemodynamic stability. Those with hypotension or decreased level of consciousness due to AF should undergo immediate cardioversion. In stable HF patients with onset of AF, rate control and prevention of thromboembolic events are the initial focus. Anticoagulation will be discussed later. Once the patient is stabilized and the ventricular rate controlled, long-term management of AF becomes the main consideration. A discussion of rate control and rhythm control follows.
Rate Control
Drugs that may be used to achieve rate control are digoxin, beta blockers, verapamil, diltiazem, and amiodarone. Digoxin slows atrioventricular (AV) conduction mostly at rest, but is ineffective during periods of sympathetic stimulation and therefore is not effective during exercise. Beta blockers slow AV conduction both at rest and with exercise and therefore are preferred for this reason as well as their associated benefits to overall outcome in HF patients. 3 The target ventricular rate should be less than 80 to 90 beats per minute at rest and 110 to 130 beats per minute during moderate exercise. 3 Refer to Table 1 for dosage recommendations.
Three beta blockers, carvedilol, metoprolol succinate, and bisoprolol, have been shown to significantly reduce mortality in the HF population. [15] [16] [17] [18] There have been questions about the effectiveness of beta blockers in HF patients with persistent AF. The Second Cardiac Insufficiency Study (CIBIS-II) compared the effects of bisoprolol, a beta-1 selective antagonist, between patients in sinus rhythm versus those in AF. 15 Bisoprolol reduced cardiovascular mortality and hospitalization for HF in patients with sinus rhythm, but not in patients with AF. In this study the predominant etiology for the HF was ischemia.
There is evidence that metoprolol succinate and carvedilol are effective in HF patients with persistent AF. In the US Carvedilol Study, use of carvedilol, a nonselective ␤ 1 -and ␤ 2 -adrenergic receptor agonist, showed significant improvement in left-ventricular ejection fraction (LVEF) and physician global assessment in patients with HF and persistent AF. 19 There was also a reduction in the combined end point of death or hospitalization for HF. Meng et al studied 70 HF patients with New York Heart Association classes II to IV symptoms and LVEF less than 40% who were treated with metoprolol succinate or carvedilol over 16 weeks. Twenty-four patients had persistent AF and 46 patients were in sinus rhythm during the course of the study. There was a higher rise in LVEF and further lowering of brain natriuretic peptide levels in the AF group than that in the sinus rhythm group during the 16-week period in both the metoprolol succinate and the carvedilol groups. 20 The majority of these patients had a nonischemic etiology for their HF.
A recent study addressed the issue of carvedilol alone versus in combination with digoxin for management of AF in HF patients. 21 This study of 47 patients with persistent AF and HF (mean LVEF 24%) indicated that the combination of carvedilol and digoxin appeared generally superior to either carvedilol or digoxin alone. In this study, both LVEF and symptom scores improved with combination therapy, whereas LVEF fell and mean ventricular rate rose when patients were switched from combination therapy to carvedilol alone.
Verapamil and diltiazem both depress myocardial function and should be avoided in HF patients with systolic dysfunction. Amiodarone may be considered if beta blockers are contraindicated.
Rate control may have advantages over rhythm control in certain HF patients. Those with markedly dilated left atria, those with AF of long duration, and those with antiarrhythmic drug toxicity may benefit from the rate control method of AF management.
Of note, besides beta-blocker use, there is evidence that the use of the angiotensin-converting enzyme inhibitors in patients with LV dysfunction who are in sinus rhythm markedly reduces the risk of development of AF. 22 This may be due to prevention of atrial dilation and stretch-induced arrhythmias or blocking the renin-angiotensin system.
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Rhythm Control-Pharmacologic Cardioversion
Restoration of sinus rhythm is most warranted for those patients with worsening symptoms that can be attributed to loss of atrial kick from AF. Although cardioversion frequently restores sinus rhythm in HF patients, only 25% of these patients remain in sinus rhythm 12 months later. 24 Patients with HF are particularly prone to the ventricular proarrhythmic effects of antiarrhythmic drugs. Class I agents are associated with increased risk of sudden death when compared to no antiarrhythmic or amiodarone in HF patients. 25, 26 In addition, class I agents may exacerbate HF or produce noncardiac toxicities. Two class III agents, amiodarone and dofetilide, have been safely used in HF patients with AF.
Amiodarone
Amiodarone does not increase the risk of death among HF patients with AF. 27 The Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT) looked at 667 patients with dilated cardiomyopathy, LVEF less than 40%, New York Heart Association classes II to IV, in either AF or sinus rhythm. They were randomized to either amiodarone or placebo and followed for a minimum of 1 year. 28 Dosing was 800 mg daily for the first 2 weeks, 400 mg daily for the next 50 weeks, and then 300 mg daily for the remainder of the study.
Atrial Fibrillation in the Heart Failure Population S5 This study showed amiodarone was more effective than placebo in converting patients with AF to sinus rhythm and in preventing development of new-onset AF. It lowered ventricular rate for more than 1 year in 50% of patients. The survival rate was higher for those patients who converted to sinus rhythm than for those who remained in AF. Studies suggest that patients who convert to sinus rhythm on chronic amiodarone therapy have a significantly better prognosis. 28, 29 Because the proarrhythmic risk of amiodarone is low, it rarely requires initiation in a hospital setting. Further evidence of benefit from low-dose amiodarone was demonstrated in the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial. 30 Although not designed to study AF in the HF population, it showed that those with severe HF taking low-dose amiodarone, 300 mg/d, had decreased mortality and hospital admissions.
Serious side effects may occur with amiodarone use, and this caused discontinuation of the drug because of either real or perceived toxic effects in 41% of patients in randomized trials. 27 Amiodarone may cause pulmonary toxicity, usually occurring in patients receiving doses greater than 300 mg/d. 24 Routine pulmonary function testing and chest x-rays are warranted at baseline drug initiation and then at regular intervals (every 6 months to 1 year). Other dose-related side effects include tremor, nausea, and peripheral neuropathy, usually subsiding with dose reduction. Non-dose-related side effects are photosensivity, opacities in the cornea and lens, blue-gray skin discoloration, hepatotoxicity, and either hypoor hyperthyroidism. Patients are advised to use sunblock. Hypothyroidism may be controlled with thyroid replacement without stopping amiodarone. Hyperthyroidism usually requires withdrawal from amiodarone, and consultation with an endocrinologist for treatment. Baseline TSH and LFT levels are warranted at baseline and regular intervals, generally every 3 to 6 months.
Amiodarone has an extremely long half-life. Loading dose is variable and usually given until a dose of 10 g is received. It has been shown to be effective on a maintenance dose as low as 200 mg/d. 24 See Table 2 for the recommended doses. In a review of studies, 16% to 71% of patients converted to sinus rhythm during amiodarone loading. 24 Of note, amiodarone interacts with many medications such as warfarin and digoxin, requiring reduction of both drug doses by 50% upon initiation of amiodarone. Since amiodarone depresses the sinus and AV nodes as does digoxin, patients must be monitored for bradycardia and digoxin toxicity.
Dofetilide
Dofetilide was found to be effective in the pharmacologic conversion of AF to sinus rhythm in several studies. The Danish Investigations of Arrhythmia and Mortality on Dofetilide-Congestive Heart Failure (DIAMOND-CHF) trial showed that in patients with LV dysfunction, dofetilide was effective in converting AF to sinus rhythm and had a neutral effect on mortality. 32 In this study, 80% of the patients on dofetilide versus placebo maintained sinus rhythm after 1 year. 33 The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study showed similar results. 34 Dofetilide should be dosed appropriately for creatinine clearance and monitored for QTc prolongation to minimize chances of torsade de pointes. Once this adjustment has been made, the risk of proarrhythmic events is low. 34 Patients should have a creatinine clearance of greater than 20 mL/min. Starting doses of 500, 250, and 125 mcg b.i.d. are used for creatinine Table 2 ). Patients should be monitored in the hospital for the first 3 days of dofetilide initiation. Renal function and QTc should be monitored every 3 months or as medically warranted. It should be discontinued for QTc more than 500 milliseconds (550 milliseconds in patients with ventricular conduction abnormalities). 35 There are a number of considerations for starting dofetilide. It may only be dispensed to hospitals and providers who have undergone specific dosing and initiation education. Therefore, it cannot be dispensed by regular pharmacies and is instead dispensed by one pharmacy and mailed to the patient's address. Patients are usually told to bring their dofetilide with them if they are ever admitted to the hospital because the hospital may not have a supply.
There are also drug-drug interactions to consider. Approximately 80% of dofetilide is excreted in the urine and eliminated by cationic renal secretion. Therefore, drugs that inhibit this process (such as cimetidine, trimethoprim, and ketoconazole) should not be given. 35 Drugs that interfere with metabolism or renal elimination of dofetilide may increase the QTc interval and the risk of torsade de pointes. Drugs that prolong the QTc interval should not be given with dofetilide. Class I or III agents should be withheld for at least 1 to 3 half-lives prior to starting dofetilide. 35 Finally, dofetilide is metabolized to a small degree by the CYP3A4 isoenzyme of the cytochrome P450 system and an inhibitor of this system could increase systemic dofetilide.
Rhythm Control-Nonpharmacologic Cardioversion
Direct-current cardioversion is an electric shock synchronized with the intrinsic activity of the heart, so that the electrical stimulation does not occur during the vulnerable phase of the cardiac cycle. It is performed under conscious sedation. It usually requires an initial energy of 200 J or greater, since levels of energy less than that have been found ineffective. 36 Unless electrical cardioversion is done emergently because of hemodynamic compromise, the patient should be anticoagulated prior to the procedure. Proarrhythmias may occur with electrical cardioversion, so electrolytes and digoxin levels should be checked prior to the procedure.
Electrical cardioversion has a success rate of 67% to 94%. 36 In patients with a dilated left atrium or AF of long duration, the success rates may be lower. In these patients, pretreatment with antiarrhythmic medication may be helpful. One study showed that in those patients who failed electrical cardioversion and were then loaded with oral amiodarone, 18% converted during the loading period and 59% had successful repeat cardioversions. 31 In those patients, 52% maintained sinus rhythm on a maintenance dose of amiodarone (200 mg/d).
Preventing Thromboembolism
Each year, 60,000 strokes occur among 2.3 million Americans with AF. 37 Strokes associated with AF are especially large and disabling. The relative risk for ischemic stroke and systemic embolism in HF patients is 1.4. 38 The risk of thromboembolism is particularly greatest when AF has been present for greater than 48 hours.
Transesophageal echocardiography is considered for patients with AF for less than 48 hours who need urgent cardioversion. It is the most sensitive and specific imaging tool for detection of left atrial or left atrial appendage thrombus. 38 Presence of left atrial or left atrial appendage thrombus is a contraindication to cardioversion. Patients with known thrombus formation should be treated with anticoagulation for 3 to 4 weeks prior to cardioversion.
Thromboembolic events occur in 1% to 7% of patients who were not anticoagulated prior to cardioversion. 38 The risk of thromboembolism is 1% in patients who are treated with warfarin, with an international normalized ratio of 2.0 to 3.0 for 3 to 4 weeks prior to cardioversion. 31 A meta-analysis of trials for primary prevention of thromboembolism in patients with nonvalvular AF revealed that adjusted-dose oral anticoagulation with warfarin reduces risk of all types of strokes (both ischemic and hemorrhagic) by 62%. 39 The percentage of risk reduction for secondary prevention was similar. Primary prevention of ischemic stroke and systemic embolism is achieved by use of warfarin in HF patients. Aspirin, 325 mg daily, is used only if there is a contraindication to warfarin use. As mentioned earlier, warfarin is adjusted to an international normalized ratio of 2.0 to 3.0. The ratio should be checked at least weekly during start of therapy and at least monthly when the level is determined to be stable. The AFFIRM trial data suggests that continuous anticoagulation is warranted in all patients with AF and risk factors for stroke, even when sinus rhythm appears to be restored and maintained. 10 According to ACC/AHA/ESC guidelines, anticoagulation may be interrupted in patients without mechanical valves for up to 1 week for procedures that have a risk for bleeding, without starting heparin therapy. 38 For high-risk patients, or those who require procedure time greater than 1 week, unfractionated or low-molecular-weight heparin may be used intravenously or subcutaneously, respectively.
A potential new agent that would dramatically change oral anticoagulation regimens is ximelagatran. This oral thrombin inhibitor agent has been studied in a series of Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials. The SPORTIF III trial was a multicenter, randomized, controlled clinical trial that compared warfarin to ximelagatran in 3410 patients with AF and one or more stroke risk factors. The primary end point of stroke or systemic embolism was 2.3% per year for warfarin and 1.6% per year for ximelagatran. There were similar rates of disabling or fatal stroke, mortality, and major bleeding between the 2 agents, but the rate of combined minor and major hemorrhages was 29.8% per year for warfarin and 25.8% per year for ximelagatran (relative risk reduction of 14%). 40 The SPORTIF V trial has been completed but has not yet been published. This agent is awaiting approval for use in the United States.
The SPORTIF III trial results did not address HF patients so it is unknown at this time if the results can be applied to this population. However, if available for this population, the benefits would be many. Ximelagatran does not require serial lab measurements for dosing, has no significant food or drug interactions, and has a rapid onset of action. It would not be used in patients with severe renal disease, hepatic disease, or other contraindications to anticoagulation therapy. Transient elevations in alanine transaminase levels have been noted. 40 
Nonpharmacologic Interventions for Refractory AF
Atrioventricular Node Ablation and Permanent Pacemaker Implantation
For patients with highly symptomatic AF and a poorly controlled ventricular response, AV node ablation is a highly effective therapy. In the electrophysiology lab, electrofrequency energy is delivered to the AV node, producing complete heart block usually with a junctional escape rhythm. A permanent pacemaker is implanted to maintain adequate heart rate, in either the single-chamber or dual-chamber mode. Patients may also be considered for biventricular pacing if mechanical dysynchrony is present. In light of the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial results, right-ventricular pacing in the HF patient should be avoided because of possible adverse outcomes. 41 Studies have shown great benefit from AV node ablation, including an increase in LVEF, improved sense of well-being, and markedly improved treadmill exercise performance. 42 
Focal Ablation
Atrial fibrillation may be triggered by a rapidly firing focus located in the pulmonary veins or in the right atrium. Radiofrequency energy delivered to these sites has been successful in eliminating AF. Success rates for pulmonary vein site ablation have been shown to be variable-from 89% if one pulmonary vein is involved to 20% if 4 pulmonary veins are involved. 42 The right atrial procedure success rate has been reported in various studies to be 15% to 50%. A newer approach is the ablation of biatrial linear lesions, with a reported success rate of 31% to 87%.
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The Maze Procedure Dr James Cox introduced the Maze procedure in 1987. This procedure involves excision of the atrial appendages and isolation of the pulmonary veins. Multiple incisions are made in both atria creating a narrow pathway that directs the sinus node impulses from across the atria to the AV node. Incisions are placed so that no area is wide enough to allow multiple reentry circuits. Several dead-end maze-like pathways are created to allow for depolarization of all the atrial tissue to occur.
The Maze procedure has a highly effective cure rate. 42 This procedure is done using cardiopulmonary bypass and thus has a higher risk of morbidity and mortality in patients with LV dysfunction. It is most useful if combined with other necessary procedures, particularly mitral valve replacement. Newer surgical approaches are being used that are simpler, such as alternate energy sources (radiofrequency, microwave, and cryothermy) and simplified left atrial lesion sets. These procedures carry a 70% to 80% cure rate. 43 
Pacemaker Therapy
It is felt that AF may be precipitated by delayed intraatrial conduction. For this reason, resynchronization of the atrial depolarization may impede development of AF. Dual-site atrial pacing (high in the right atrium and at the coronary sinus ostium) and biatrial pacing (high in the right atrium and in the mid-or proximal coronary sinus) have been used. 2 At this time, methods of overdrive atrial pacing are being explored. 44 
Conclusion
Atrial fibrillation in persons with HF presents a great challenge for management. New studies guide us to make decisions on the basis of symptoms and quality of life and offer evidence that both rate control and rhythm control are effective management strategies.
Ongoing studies will help us tailor the evidence to the HF population. Nurses who are knowledgeable about the treatment of AF can advise patients of treatment approaches and provide information that may increase medication adherence and facilitate symptom management.
